Hefei Afana Biotechnology Co., Ltd. has announced the initial closing of a $50 million Series A financing round. The round was led by Guozhong Capital, alongside several other institutions, with participation from multiple investors. The proceeds will be used to advance core pipelines, including in vivo CAR-T and tumor vaccines, upgrade the TALENT® technology platform, and strengthen CMC, regulatory development, and industrialization capabilities—thereby accelerating the clinical and subsequent development of innovative therapies. Founded in 2021, Afana Bio focuses on innovative drug R&D, with a strategic presence in three major areas. Multiple pipelines have entered key clinical stages, and the company has received support from several national-level special projects and holds nearly 100 related patents. Its self-developed TALENT® platform integrates in vivo immune cell programming with nano-delivery technology to enable in vivo reprogramming of cell functions, and several core pipelines have recently achieved important clinical progress. Heads of multiple participating institutions and company executives expressed their recognition of the company's development and future plans.